UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.
Canadian generics maker Apotex and India-based Strides Shasun will merge their Australian operations in a bid to create the leading player in the Australian generics pharmaceutical market.
AstraZeneca has agreed to sell its rights to Seroquel (quetiapine fumarate) and Seroquel XR to China-based pharmaceutical company Luye Pharma Group for $538 million.
Biopharmaceutical company Celgene has ditched its trademark quarrel with the owners of India-based online pharmacies importing generics into the US.
China’s State Intellectual Property Office has granted Merck KGaA a patent covering its CRISPR technology used in a genomic-integration method for eukaryotic cells.
Japan-based Takeda has upped its offer to buy Ireland-headquartered Shire for the fourth time, raising its bid to approximately £44 billion.
China’s government has announced a series of measures to increase the country’s importation of drugs, including enhanced IP protection in the pharmaceutical industry.
China’s government has announced plans to implement preferential tax rates to generic drug makers in a bid to encourage the manufacturing of generics.
Japan-based Fujifilm has revealed its plan to acquire two cell culture media companies for $800 million.
Eisai has partnered with fellow Japanese pharmaceutical company Nichi-Iko Pharmaceutical to expand and grow Nichi-Iko’s generic business.